X-Linked Hypophosphatemia Market Research Report - Global Forecast till 2025

Global X-Linked Hypophosphatemia Market: By Treatment (Medication, Surgical, or Orthopedic Treatment), End User (Hospitals and Clinics, Research Centers) & Region (Americas, Europe, Asia-Pacific & RoW) - Forecast till 2025

ID: MRFR/LS/4806-CR | August 2019 | Region: Global | 73 pages

The Global X-Linked Hypophosphatemia Market is expected to register a CAGR of 3.6% to reach USD 40,309.1 Thousand by 2025.
X-linked hypophosphatemia (XLH) is an inherited disorder characterized by low levels of phosphate in the blood. The phosphate levels reduce as it is abnormally processed in the kidneys, which leads to the loss of phosphate through urine (phosphate wasting) and leads to soft and weak bones, causing rickets. XLH is usually diagnosed in childhood, and symptoms include bowed or bent legs, short stature, bone pain, and severe dental pain. XLH is caused by mutations in the PHEX gene on the X chromosome, and the inheritance of the X-linked is dominant. The treatment generally involves supplements of phosphate and high-dose calcitriol (an active form of vitamin D) and may also include growth hormones and corrective surgery. The key factors responsible for driving the market are the increasing prevalence rates of XLH, growing awareness about XLH. However, negative psychological and emotional impacts of having X-linked hypophosphatemia, post-operative complications, unfavorable drug price control policies in many countries, increasing penetration of counterfeit drugs, and complex license renewal procedures are hindering the growth of the global X-linked hypophosphatemia market.
Market Dynamics
XLH is an inherited phosphate metabolism disorder in which inactivating mutations of the PHEX gene lead to local and systemic effects such as impaired growth, rickets, hearing difficulties, enthesopathy, osteomalacia, bone pain, bone abnormalities, spontaneous dental abscesses, osteoarthritis, and muscular dysfunction. Due to the rising cases of XLH in developing and developed economies, the global XLH market is expected to grow at a steady rate during the forecast period. For instance, according to the European Journal of Endocrinology statistics published in 2016, the incidence of XLH has been estimated to be 3.9 per 100,000 live births and has a prevalence of 4.8 per 100,000 people. Also, according to the study published in May 2016 by NIHR Horizon Scanning Research & Intelligence Centre, XLH affected more than 500 children in the UK.
Similarly, according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. And according to a report published in 2017 by the National Institute for Health and Care Excellence, there were approximately 250 children and young people with XLH in England, and up to 2,500 adults, till date. Thus, the overall market growth is projected to rise owing to the rising prevalence rates of XLH, which required adequate drugs and therapies for treatment.
Global X-Linked Hypophosphatemia Market Revenue, by Treatment, 2018 (USD Thousands)
 
Sources: MRFR Analysis
Segmentation
The X-linked hypophosphatemia (XLH) market by treatment has been segmented into medication and Surgical or orthopedic treatment. The X-linked hypophosphatemia market has been categorized by the end user into hospitals and clinics and research centers. The research centers segment is expected to account for the largest market share during the forecast period attributing to the increasing prevalence of XLH, increasing awareness regarding the disease, and growing research activity for its treatment.
The global X-linked hypophosphatemia market, by region, is segmented into the Americas, Europe, Asia-Pacific, and RoW. Factors such as the increasing prevalence of XLH and increasing awareness about the disorder are anticipated to propel the growth of the global X-Linked hypophosphatemia market.
Global X-linked Hypophosphatemia Market Share, by Region, 2018 (%)    
            
Sources: MRFR Analysis
Regional Analysis
The XLH market in the Americas is expected to hold a major market share owing to the growing prevalence of XLH in the US and Canada and the presence of a well-established healthcare sector. The rising research funding towards rare diseases such as XLH and the high healthcare expenditure is also expected to fuel the growth of the market during the forecast period. For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology. Similarly, the International Rare Diseases Research Consortium (IRDiRC) is a Scientific Secretariat that works in collaboration with Orphanet. Since 2010, IRDiRC financed over 3,000 projects. Moreover, according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US. Moreover, the rising government funding for the healthcare sector, the increasing prevalence rate of rare diseases, and research funding are expected to propel the growth of the market in this region.
Key Players
The prominent players in the global X-linked hypophosphatemia (XLH) market are Ultragenyx Pharmaceutical, Validus Pharmaceuticals LLC, Prospec-Tany Technogene Ltd, Merck KGaA, Zeria Pharmaceutical Co., Ltd, Smith & Nephew, Narang Medical Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Others.
The players operating in the global X-linked hypophosphatemia (XLH) market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
Market Segmentation
Global X-Linked Hypophosphatemia Market, by Treatment

Medication
Surgical or Orthopedic Treatment

Global X-Linked Hypophosphatemia Market, by End User

Hospitals and Clinics
Research Centers

Global X-Linked Hypophosphatemia Market, by Region

Americas

North America

US
Canada
South America

Europe

Germany
UK
France
Spain
Italy
Rest of Europe

Asia-Pacific

China
India
Japan
Australia & New Zealand
Southeast Asia
Rest of Asia-Pacific

Rest of the World

Middle East
Africa

Available Additional Customizations
Company Profiles of Key Regional Players

Kyowa Hakko Kirin
 Smith & Nephew
Nestle
Pfizer
Koninklijke DSM
ADM Alliance Nutrition

Intended Audience

Drug Suppliers
Research and Development (R&D) Companies
Government Research Laboratories
Independent Research Laboratories
Government and Independent Regulatory Authorities
Market Research and Consulting Service Providers
Medical Research Laboratories
Academic Medical Institutes and Universities



Frequently Asked Questions (FAQ) :


X-Linked Hypophosphatemia Market CAGR would be 3.6% during the forecast period.

X-Linked Hypophosphatemia Market valuation would be USD 40309.1 thousand by 2025.

The research centers segment would X-Linked Hypophosphatemia Market.

The Americas would dominate X-Linked Hypophosphatemia Market

Players involved in X-Linked Hypophosphatemia Market are Validus Pharmaceuticals LLC, Ultragenyx Pharmaceutical, Merck KGaA, Prospec-Tany Technogene Ltd, Narang Medical Limited, Zeria Pharmaceutical Co., Ltd, Smith & Nephew, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, and Others.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

USD YEN EURO GBP INR
TABLE OF CONTENT

2.1 Scope of the Study 13

2.2 Research Objective 13

2.3 List of Assumptions 14

3.1 Research Methodology - X-Linked Hypophosphatemia Market 15

3.2 Data Mining 16

3.3 Secondary Research 16

3.3.1 Data points received from the secondary research 17

3.4 Primary Research 17

3.4.1 Data points received from surgeons, & consulting physicians 18

3.4.2 Data points received from the manufacturer 19

3.5 Forecasting Techniques 19

3.6 Research Methodology for Market Size Estimation X-Linked Hypophosphatemia Market: 20

3.6.1 Assumptions 21

3.7 Data Triangulation 22

3.8 Validation 22

4.1 Overview 23

4.2 Drivers 24

4.2.1 Increasing Prevalence Rate of XLH 24

4.2.2 Growing Awareness about XLH 24

4.2.3 Increasing Research 24

4.2.4 Driver Impact Analysis 25

4.3 Restraints 26

4.3.1 Side-Effects Associated with Burosumab 26

4.3.2 High Cost of Burosumab 26

4.3.3 Limited Availability of Treatment Options 26

4.3.4 Restraint Impact Analysis 27

4.4 Opportunity 28

4.4.1 Recent Regulatory Approvals 28

5.1 Value Chain Analysis 29

5.1.1 Overview 29

5.1.2 R&D 29

5.1.3 Manufacturing 29

5.1.4 Distribution and Sales 29

5.1.5 Post-Sales Monitoring 30

5.2 Porter’s Five Forces Model 31

5.2.1 Overview 31

5.2.2 Bargaining Power of Suppliers 32

5.2.3 Bargaining Power of Buyers 32

5.2.4 The threat of New Entrants 32

5.2.5 Threat of Substitutes 32

5.2.6 Intensity of Rivalry 32

6.1 Introduction 33

6.2 Medication 34

6.3 Surgical or Orthopedic Treatment 34

7.1 Introduction 35

7.2 Hospitals and Clinics 36

7.3 Research Centers 36

8.1 Introduction 37

8.2 Americas 39

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.1 North America 40

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.1.1 US 41

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.1.2 Canada 42

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.2.2 South America 42

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3 Europe 43

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.1 Germany 44

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.2 France 45

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.3 UK 45

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.4 Italy 46

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.5 Spain 46

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.3.6 Rest of Europe 47

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4 Asia-Pacific 48

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.1 China 49

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.2 Japan 50

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.3 India 50

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.4 South Korea 51

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.5 Australia 51

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.4.6 Rest of Asia-Pacific 52

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

8.5 RoW 53

X-Linked Hypophosphatemia Market, by Treatment

X-Linked Hypophosphatemia Market, by End User

9.1 Introduction 54

9.2 Key developments 55

10.1 Ultragenyx Pharmaceutical 57

10.1.1 Company Overview 57

10.1.2 Financial Overview 57

10.1.3 Products/Services Offered 58

10.1.4 Key Developments 58

10.1.5 SWOT Analysis 58

10.1.6 Key Strategies 59

10.2 Validus Pharmaceuticals LLC 60

10.2.1 Company Overview 60

10.2.2 Financial Overview 60

10.2.3 Products/Services Offered 60

10.2.4 Key Developments 60

10.2.5 SWOT Analysis 60

10.2.6 Key Strategies 61

10.3 Prospec-Tany Technogene Ltd 62

10.3.1 Company Overview 62

10.3.2 Financial Overview 62

10.3.3 Products/Services Offered 62

10.3.4 Key Developments 62

10.3.5 SWOT Analysis 63

10.3.6 Key Strategies 63

10.4 Merck KGaA 64

10.4.1 Company Overview 64

10.4.2 Financial Overview 64

10.4.3 Products/Services Offered 64

10.4.4 Key Developments 65

10.4.5 SWOT Analysis 65

10.4.6 Key Strategies 65

10.5 Zeria Pharmaceutical Co., Ltd 66

10.5.1 Company Overview 66

10.5.2 Financial Overview 66

10.5.3 Products/Services Offered 66

10.5.4 Key Developments 66

10.5.5 SWOT Analysis 67

10.5.6 Key Strategies 67

10.6 Smith & Nephew 68

10.6.1 Company Overview 68

10.6.2 Financial Overview 68

10.6.3 Products/Services Offered 68

10.6.4 Key Developments 69

10.6.5 SWOT Analysis 69

10.6.6 Key Strategies 69

10.7 Narang Medical Limited 70

10.7.1 Company Overview 70

10.7.2 Financial Overview 70

10.7.3 Products/Services Offered 70

10.7.4 Key Developments 70

10.7.5 SWOT Analysis 71

10.7.6 Key Strategies 71

10.8 Eli Lilly and Company 72

10.8.1 Company Overview 72

10.8.2 Financial Overview 72

10.8.3 Products/Services Offered 72

10.8.4 Key Developments 73

10.8.5 SWOT Analysis 73

10.8.6 Key Strategies 73

10.9 F. Hoffmann-La Roche Ltd 74

10.9.1 Company Overview 74

10.9.2 Financial Overview 74

10.9.3 Products/Services Offered 74

10.9.4 Key Developments 75

10.9.5 SWOT Analysis 75

10.9.6 Key Strategies 75

10.10 Illumina, Inc. 76

10.10.1 Company Overview 76

10.10.2 Financial Overview 76

10.10.3 Products/Services Offered 77

10.10.4 Key Developments 77

10.10.5 SWOT Analysis 78

10.10.6 Key Strategies 78

10.11 Biomedica Medizinprodukte GmbH 79

10.11.1 Company Overview 79

10.11.2 Financial Overview 79

10.11.3 Products/Services Offered 79

10.11.4 Key Developments 79

10.11.5 SWOT Analysis 79

10.11.6 Key Strategies 80

10.12 QIAGEN 81

10.12.1 Company Overview 81

10.12.2 Financial Overview 81

10.12.3 Products/Services Offered 82

10.12.4 Key Developments 82

10.12.5 SWOT Analysis 82

10.12.6 Key Strategies 82

11.1 References 83

11.2 Related Reports 83


TABLE 1 LIST OF ASSUMPTIONS 14

TABLE 2 PORTER’S FIVE FORCES ANALYSIS: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET 31

TABLE 3 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 33

TABLE 4 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR MEDICATION, BY REGION 2016–2025 (USD THOUSANDS) 34

TABLE 5 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR SURGICAL OR ORTHOPEDIC TREATMENT, BY REGION 2016–2025

(USD THOUSANDS) 34

TABLE 6 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 35

TABLE 7 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR HOSPITALS AND CLINICS, BY REGION 2016–2025 (USD THOUSANDS) 36

TABLE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET FOR RESEARCH CENTERS, BY REGION 2016–2025 (USD THOUSANDS) 36

TABLE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 2016–2025 (USD THOUSANDS) 38

TABLE 10 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY REGION 2016–2025 (USD THOUSANDS) 39

TABLE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 39

TABLE 12 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 40

TABLE 13 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY 2016–2025 (USD THOUSANDS) 40

TABLE 14 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 41

TABLE 15 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 41

TABLE 16 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 41

TABLE 17 US: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 41

TABLE 18 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 42

TABLE 19 CANADA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 42

TABLE 20 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 42

TABLE 21 SOUTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 42

TABLE 22 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 2016–2025 (USD THOUSANDS) 43

TABLE 23 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 44

TABLE 24 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 44

TABLE 25 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 44

TABLE 26 GERMANY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 44

TABLE 27 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 45

TABLE 28 FRANCE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 45

TABLE 29 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 45

TABLE 30 UK: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 45

TABLE 31 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 46

TABLE 32 ITALY: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 46

TABLE 33 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 46

TABLE 34 SPAIN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 46

TABLE 35 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 47

TABLE 36 REST OF EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 47

TABLE 37 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY COUNTRY/REGION 2016–2025 (USD THOUSANDS) 48

TABLE 38 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 49

TABLE 39 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 49

TABLE 40 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 49

TABLE 41 CHINA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 49

TABLE 42 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 50

TABLE 43 JAPAN: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 50

TABLE 44 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 50

TABLE 45 INDIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 50

TABLE 46 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 51

TABLE 47 SOUTH KOREA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 51

TABLE 48 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 51

TABLE 49 ASUTRALIA: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 51

TABLE 50 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 52

TABLE 51 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 52

TABLE 52 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2016–2025 (USD THOUSANDS) 53

TABLE 53 ROW: X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2016–2025 (USD THOUSANDS) 53

TABLE 54 KEY DEVELOPMENTS, BY PLAYERS IN THE MARKET 55



FIGURE 1 MARKET SYNOPSIS 12

FIGURE 2 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET: STRUCTURE 14

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 21

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL GROWTH HORMONE MARKET 23

FIGURE 5 DRIVER IMPACT ANALYSIS 25

FIGURE 6 RESTRAINT IMPACT ANALYSIS 27

FIGURE 7 SUPPLY CHAIN: GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET 29

FIGURE 8 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY TREATMENT 2018 & 2025 (USD THOUSANDS) 33

FIGURE 9 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET, BY END USER 2018 & 2025 (USD THOUSANDS) 36

FIGURE 10 GLOBAL X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2018 (%) 38

FIGURE 11 AMERICAS: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY REGION 2018 (%) 39

FIGURE 12 NORTH AMERICA: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY 2018 (%) 40

FIGURE 13 EUROPE: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2018 (%) 43

FIGURE 14 ASIA-PACIFIC: X-LINKED HYPOPHOSPHATEMIA MARKET SHARE, BY COUNTRY/REGION 2018 (%) 48

FIGURE 15 MAJOR PLAYERSCATEGORY-WISE SHARE OF KEY DEVELOPMENTS 56